Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Investigators in the Division of Infectious Diseases and the Departments of Biochemistry and Molecular Biology of The George Washington University Medical Center are carrying out a research study to determine why patients with Human Immunodeficiency Virus (HIV) and Hepatitis C virus (HCV) co-infection (HIV/HCV) have a more rapid and progressive course of HCV infection, leading to fatty infiltration of the liver and cirrhosis.
Samples will be collected from 4 groups of patients with HIV/HCV infection, identified by the virologic control of either HIV, HCV, or both. Sera will be used in an in-vitro hepatocyte model of hepatitis C infection to better understand the pathogenesis of HIV/HCV co-infection, and to gain insight into intracellular mechanisms.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Detectable HIV RNA and HCV RNA | HIV and HCV co-infected with detectable HIV RNA and HCV RNA | ||
| Undetectable HIV and Detectable HCV | HIV and HCV infected, HIV RNA Undetectable(treated) and Detectable HCV RNA. | ||
| Undetectable HIV and HCV | HIV and HCV infected, Undetectable HIV RNA and HCV RNA | ||
| Undetectable HCV | HCV(mono-infected,) HCV RNA undetectable | ||
| Detectable HCV RNA | Monoinfected HCV, detectable RNA | ||
| Detectable HIV RNA | Monoinfected HIV, Detectable RNA |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Laboratory analysis of Tat Protein | The validation that HIV Tat protein is a potent inducer of HCV in dual infected patients will likely lead to anti-tat therapy to manage HCV patients for whom treatment options are rather limited. | Single sample analysis |
Not provided
Not provided
Inclusion Criteria:
Meets one of the following criteria:
Participants will be men and women, ages 18 and older, and who are patients being seen in the clinics of the Medical Faculty Associates, and meet the above criteria.
Exclusion Criteria:
Not provided
Not provided
Not provided
Four groups of subjects will be included in this study, with 5 participants in each group:
Not provided
| Name | Affiliation | Role |
|---|---|---|
| David Parenti, MD | George Washington University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| George Washington University Medical Faculty Associates | Washington D.C. | District of Columbia | 20037 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000163 | Acquired Immunodeficiency Syndrome |
| D019698 | Hepatitis C, Chronic |
| ID | Term |
|---|---|
| D015658 | HIV Infections |
| D000086982 | Blood-Borne Infections |
| D003141 | Communicable Diseases |
| D007239 | Infections |
Not provided
Not provided
Not provided
Not provided
Not provided
| D015229 |
| Sexually Transmitted Diseases, Viral |
| D012749 | Sexually Transmitted Diseases |
| D016180 | Lentivirus Infections |
| D012192 | Retroviridae Infections |
| D012327 | RNA Virus Infections |
| D014777 | Virus Diseases |
| D012897 | Slow Virus Diseases |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D007153 | Immunologic Deficiency Syndromes |
| D007154 | Immune System Diseases |
| D006526 | Hepatitis C |
| D006525 | Hepatitis, Viral, Human |
| D018178 | Flaviviridae Infections |
| D006521 | Hepatitis, Chronic |
| D006505 | Hepatitis |
| D008107 | Liver Diseases |
| D004066 | Digestive System Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |